Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Farmers Insurance
Argus Health
McKesson
Cipla
Mallinckrodt
Fuji
AstraZeneca
Colorcon
McKinsey

Generated: January 17, 2018

DrugPatentWatch Database Preview

TRILAFON Drug Profile

« Back to Dashboard

Which patents cover Trilafon, and when can generic versions of Trilafon launch?

Trilafon is a drug marketed by Schering and is included in five NDAs.

The generic ingredient in TRILAFON is perphenazine. There are eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the perphenazine profile page.
Drug patent expirations by year for TRILAFON
Medical Subject Heading (MeSH) Categories for TRILAFON

US Patents and Regulatory Information for TRILAFON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering TRILAFON perphenazine CONCENTRATE;ORAL 011557-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Schering TRILAFON perphenazine TABLET;ORAL 010775-003 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Schering TRILAFON perphenazine TABLET, EXTENDED RELEASE;ORAL 011361-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Schering TRILAFON perphenazine TABLET;ORAL 010775-004 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Schering TRILAFON perphenazine INJECTABLE;INJECTION 011213-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Schering TRILAFON perphenazine SYRUP;ORAL 011294-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Schering TRILAFON perphenazine TABLET;ORAL 010775-002 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Schering TRILAFON perphenazine TABLET;ORAL 010775-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Johnson and Johnson
Mallinckrodt
Medtronic
Cipla
QuintilesIMS
Julphar
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot